Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis. (2022)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.jhepr.2022.100544
PubMed Identifier: 36267872
Publication URI: http://europepmc.org/abstract/MED/36267872
Type: Journal Article/Review
Volume: 4
Parent Publication: JHEP reports : innovation in hepatology
Issue: 11
ISSN: 2589-5559